

Methylprednisolone versus dexamethasone in patients with COVID-19

Submission date 21/01/2022	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 24/01/2022	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 24/10/2022	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Since the beginning of the COVID-19 pandemic, corticosteroids have been used to control the inflammatory response. Inflammation is normal in response to injury or infection, but it can be dangerous if it is not controlled.

The present study aims to evaluate the efficacy of early intravenous administration of methylprednisolone in all-cause mortality rates at 28 days after randomization in adult patients with COVID-19.

Who can participate?

Adults over the age of 18, diagnosed with COVID 19 and that needed hospitalization.

What does the study involve?

The intervention group received methylprednisolone associated with the standard treatment for COVID-19, while the control group received dexamethasone associated with the standard treatment for COVID-19.

What are the possible benefits and risks of participating?

The possible risks are the consequences of the disease itself, and the side effects of the corticosteroids that are being used in the study. As a consequence of COVID-19 it is possible to develop thromboembolic events, bleedings, need for ICU, need for respiratory support, death. Direct benefits to participants are not guaranteed. This is a study to verify the real effectiveness of a medication that is already formally recommended for the treatment of COVID-19.

Where is the study run from?

The MEDEX study is being run by the Núcleo de Pesquisa do Hospital do Rocio (Rocio Hospital Research Center) and takes place at the Hospital do Rocio (Rocio Hospital), in south Brazil.

When is the study starting and how long is it expected to run for?

July 2021 to September 2021

Who is funding the study?

Investigator initiated and funded

Who is the main contact?

1. Dalton Rivabem MD
daltonrivabem@yahoo.com.br
2. Evandro Mariot MD
evandroasm@yahoo.com.br
3. Cesar Dusilek MD
cesardusilek@gmail.com

Contact information

Type(s)

Scientific

Contact name

Mr Evandro Mariot

ORCID ID

<https://orcid.org/0000-0002-7644-747X>

Contact details

Maria Aparecida de Oliveira Street nº 599
Campo Largo - PR - Brazil
CEP: 83601-350
Campo Largo
Brazil
83601-350
-
evandroasm@yahoo.com.br

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

47957821.2.0000.5529

Study information

Scientific Title

Evaluation of the effectiveness of methylprednisolone versus dexamethasone in patients with COVID-19

Acronym

MEDEX

Study objectives

The early administration of methylprednisolone increases the number of days alive and free from mechanical ventilation, and / or reduces the length of hospital stay, in adult patients with moderate or severe acute respiratory syndrome resulting from COVID-19.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 27/07/2021, Brazilian National Research Ethics Committee (Brasília - Distrito Federal - Brazil, North Wing, SRTV 701, Via W 5 Norte, lote D - Edifício PO 700, 3º floor, CEP: 70719-040; + 55 61 3315-5878; conep@saude.gov.br), ref: 47957821.2.0000.5529

Study design

Prospective randomized controlled single-center open comparative clinical trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

COVID-19 (SARS-CoV-2 infection)

Interventions

The study presents two groups. The "Rocio Group" is the intervention group, while the "Recovery Group" is the control group.

The intervention group received daily intravenous methylprednisolone for 3 days, followed by a daily dose of 1 mg/kg/day for 7 days. The control group received a daily dose of 6 mg of dexamethasone intravenously for 10 days or until discharge, whichever comes first.

Both groups received standard care for critically ill and potential critical patients. The standard care included: follow-up diary by the Assistant Physician in the infirmary unit; Monitoring by the ICU Diarist Physician; monitoring, adjustment of conducts and care of intercurrents by the ICU on-duty Physician (for patients in ICU); continuous hemodynamic and ventilatory monitoring; monitoring of vital data following the ICU routine (for patients in ICU); motor and respiratory physiotherapy; ventilatory support measures, invasive or not; hemodynamic support measures, with or without vasopressors, as medically indicated (for patients in ICU); hydro-electrolyte and acid-base control; medical and general procedures, such as central venous access puncture, closed chest drainage, tracheostomy, among others; use of antimicrobials (antibiotics, antivirals, antifungals, bacteriostatics, etc). according to medical advice; any treatment used adjunct that does not interfere with the evaluation; laboratory routine according to the unit routine and/or medical indication.

Follow-up included laboratory data on the third day, on the seventh day, on tenth day of randomization and on discharge day. All patients were followed until day 28 after randomization. The study is a single randomized paired into two equal groups. Randomization took place in the ward the day after hospital admission and was carried out by the research coordinator and informed to the assistant physician. The study is not blinded randomization, however, the statistical analysis of data is blinded.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Methylprednisolone, dexamethasone

Primary outcome(s)

All-cause mortality rates at 28 days after randomization measured using patient records

Key secondary outcome(s)

Measured using patient records:

1. Length of hospital stay
2. Need or not for referral to the ICU
3. Length of ICU stay between randomization and day 28
4. Time of mechanical ventilation between randomization and day 28
5. Changes in laboratory standards after 72 hours, 7 days and 10 days of randomization

Completion date

30/09/2021

Eligibility

Key inclusion criteria

1. Age ≥ 18 years.
2. Confirmed or suspected infection for COVID-19.
3. Need for hospitalization, infirmary or intensive care unit (ICU).
4. Chest tomography with image compatible with COVID-19.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

400

Key exclusion criteria

1. Known history of allergy to metrilprednisolone.
2. Use of corticosteroids for another condition.
3. Patient's refusal to participate in the study.
4. Pregnant or breastfeeding women.
5. Contraindication to the use of corticosteroids.

Date of first enrolment

15/08/2021

Date of final enrolment

20/09/2021

Locations

Countries of recruitment

Brazil

Study participating centre**Hospital do Rocio**

Maria Aparecida de Oliveira Street nº 599

Campo Largo

Brazil

83601-350

Sponsor information

Organisation

Hospital do Rocio

Funder(s)

Funder type

Other

Funder Name

Investigator initiated and funded

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study will be published as a supplement to the subsequent results publication

IPD sharing plan summary

Published as a supplement to the results publication

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Other unpublished results			24/10/2022	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Protocol file	version 2	06/07/2021	24/01/2022	No	No